Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart
failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin …

Aims An algorithm for non‐invasive diagnosis of amyloid transthyretin cardiac amyloidosis
(ATTR‐CA) and novel disease‐modifying therapies have prompted an active search for CA …

The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …

Transthyretin (TTR) is a tetrameric protein synthesized mostly by the liver and secreted into
the plasma. TTR molecules can misfold and form amyloid fibrils in the heart and peripheral …

Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an
underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils …

Background: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly
recognized cause of heart failure in older individuals. We sought to characterize the natural …

Background—Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive,
infiltrative disease caused by the deposition of transthyretin amyloid fibrils in the heart, and …

The prevalence of calcific aortic stenosis (AS) and of cardiac amyloidosis (CA) increases
with age, and their association is not uncommon in the elderly. The identification of CA is …

Tissue deposition of protein fibrils causes a group of rare diseases called systemic
amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach …